Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:40 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 10,545 matching trials from the live ClinicalTrials.gov search.
Filters: Cincinnati, Ohio Clear all
Completed Phase 4 Interventional Results available

Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics

NCT02360319
View directory record Official record
Conditions
Schizophrenia
Interventions
Any FDA approved antipsychotic agent, aripiprazole long acting injectable formulation
Drug
Lead sponsor
Vanguard Research Group
Other
Eligibility
18 Years to 35 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
39
States / cities
Tucson, Arizona • Granada Hills, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Nov 1, 2026, 4:40 AM EST
Completed Not applicable Interventional

Bowel Preparation and Pelvic Organ Prolapse Surgery

NCT00937430
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Bowel preparation (Fleets enema)
Other
Lead sponsor
TriHealth Inc.
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2014 · Synced Nov 1, 2026, 4:40 AM EST
Completed No phase listed Observational

Study of Markers of Cosmic Radiation Exposure and Effect Among Flight Crews

NCT00341900
View directory record Official record
Conditions
Frequency of Chromosome Aberrations
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
25 Years to 60 Years · Male only
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Nov 1, 2026, 4:40 AM EST
Terminated Phase 2 Interventional Results available

Phase 2, Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Metastatic Pancreatic Cancer

NCT02570711
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
ACP-196, Nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Ventura, California • Fort Myers, Florida • Durham, North Carolina + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Nov 1, 2026, 4:40 AM EST
Terminated Phase 2 Interventional Results available

The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation

NCT03339401
View directory record Official record
Conditions
Adenovirus
Interventions
Standard of Care, Brincidofovir
Other · Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Months to 25 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Nov 1, 2026, 4:40 AM EST
Completed Not applicable Interventional

Atazanavir/Ritonavir Maintenance Therapy

NCT00084019
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Palo Alto, California • Aurora, Colorado • Honolulu, Hawaii + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Nov 1, 2026, 4:40 AM EST
Terminated Not applicable Interventional

Pharmacogenomics Information in Enhancing Post-operative Total Joint Replacement Pain Management: a Pilot Study

NCT02711592
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee, Pain, Postoperative
Interventions
Genetic Panel for Analgesics
Genetic
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2021 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison of Flu Vaccine Doses in Children

NCT01164553
View directory record Official record
Conditions
Influenza
Interventions
Trivalent Inactivated Influenza Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 35 Months
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
7
States / cities
Atlanta, Georgia • Iowa City, Iowa • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Nov 1, 2026, 4:40 AM EST
Terminated Phase 3 Interventional Results available

Study of Ataluren in Previously Treated Participants With Nonsense Mutation Dystrophinopathy (nmDBMD)

NCT01247207
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Male only
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
29
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 1, 2026, 4:40 AM EST
Completed Not applicable Interventional

Misago® RX Self-expanding Peripheral Stent for Common and/or External Iliac Artery

NCT02793492
View directory record Official record
Conditions
Iliac Artery Stenosis
Interventions
Misago® RX Self-expanding Peripheral Stent
Device
Lead sponsor
Terumo Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Thornton, Colorado • Gainesville, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Nov 1, 2026, 4:40 AM EST
Approved For Marketing No phase listed Expanded access

Expanded Access Program of Ponatinib

NCT01592136
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Interventions
ponatinib
Drug
Lead sponsor
Ariad Pharmaceuticals
Industry
Eligibility
18 Years and older
U.S. locations
33
States / cities
La Jolla, California • San Marcos, California • Vallejo, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Nov 1, 2026, 4:40 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Trial of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes

NCT02146157
View directory record Official record
Conditions
Prediabetes
Interventions
herb and mineral combination product, Placebo
Dietary Supplement
Lead sponsor
NewChapter, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
6
States / cities
Chicago, Illinois • Lexington, Kentucky • Bingham Farms, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Nov 1, 2026, 4:40 AM EST
Terminated Phase 2 Interventional Results available

Phase II, Dose Finding Study of GTx-758

NCT01393119
View directory record Official record
Conditions
Prostate Cancer
Interventions
GTx-758
Drug
Lead sponsor
GTx
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
21
States / cities
Glendale, Arizona • Phoenix, Arizona • La Mesa, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Nov 1, 2026, 4:40 AM EST
Active, not recruiting Phase 3 Interventional Results available

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

NCT04526665
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Elafibranor 80mg, Placebo
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 75 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
46
States / cities
Chandler, Arizona • Los Angeles, California • Sacramento, California + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 4 Interventional

Comparison FloShield Air System Versus Clearify Visualization System (D-HELP)

NCT02419911
View directory record Official record
Conditions
Laparoscopic Surgery
Interventions
Laparoscopic surgery, FloShield Defogging and Cleaning System, Clearify Defogging and Cleaning System
Procedure · Device
Lead sponsor
Minimally Invasive Devices, Inc.
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
South Miami, Florida • Las Vegas, Nevada • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2015 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 2 Interventional Results available

A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis

NCT03496571
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 2 Interventional Results available

Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease

NCT02489344
View directory record Official record
Conditions
Fabry Disease
Interventions
GZ/SAR402671
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients

NCT01335464
View directory record Official record
Conditions
Pulmonary Fibrosis
Interventions
placebo, BIBF 1120
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Nov 1, 2026, 4:40 AM EST
Terminated Phase 1 Interventional

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

NCT02819999
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Rovalpituzumab Tesirine, Cisplatin, Etoposide
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Aurora, Colorado • Denver, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia

NCT00876798
View directory record Official record
Conditions
Euvolemic Hyponatremia
Interventions
Lixivaptan, Placebo
Drug
Lead sponsor
CardioKine Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
66
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

NCT03969212
View directory record Official record
Conditions
Influenza
Interventions
Baloxavir Marboxil, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
5 Years to 64 Years
Enrollment
4,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Nov 1, 2026, 4:40 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

NCT06868212
View directory record Official record
Conditions
Chronic Spontaneous Urticaria (CSU)
Interventions
Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
121
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 1, 2026, 4:40 AM EST
Completed Phase 1Phase 2 Interventional Results available

ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults

NCT04856865
View directory record Official record
Conditions
Food Allergy
Interventions
Low dose ADP101, High dose ADP101, Pooled Placebo
Biological
Lead sponsor
Alladapt Immunotherapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Nov 1, 2026, 4:40 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Assess the Ingestion of Dentifrice by Children

NCT02409836
View directory record Official record
Conditions
Healthy Individuals
Interventions
Marketed Dentifrice, Marketed Flavored Dentifrice
Drug
Lead sponsor
Procter and Gamble
Industry
Eligibility
2 Years to 12 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2015 · Synced Nov 1, 2026, 4:40 AM EST